Five developments define this week's signal. Demis Hassabis is targeting disease at the biological root. Varda Space is manufacturing pharmaceuticals in microgravity orbit. A pancreatic cancer treatment is showing measurable clinical progress. Rocket upper stages are being repurposed as orbital data centers. The IPO window has reopened.
Each of these stories represents a different axis of technical ambition: biology, manufacturing, oncology, infrastructure, and capital markets. The original piece covers all five with enough specificity to distinguish real progress from noise. The space data center angle alone is worth the read: converting spent rocket hardware into compute infrastructure changes the economics of both launch and cloud.
Read the full issue for the details on Varda's drug synthesis results, the pancreatic cancer trial numbers, and what the IPO reopening actually means for deep tech funding cycles. The original does not editorialize much. It lists. That discipline is the point.
[READ ORIGINAL →]